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Medical domains involve numerous tests and treatments, the sheer variety of which confounds both care
providers and patients. Many of the decisions depend on the patient’s preferences. Shared decision-mak-
ing, which explicitly involves the patients and their preferences, is therefore imperative, but requires also
a sufﬁcient explanatory infrastructure. We introduce a distributed application, PANDEX, that, by using
decision-analytic methods, assists patients and care providers to reach optimal decisions. Based on a gen-
eric architecture, the PANDEX prototype, which focuses on the domain of genetic prenatal consultation, is
designed to calculate the optimal treatment strategy based on the patient’s clinical data and preferences.
A major focus of our study was on developing several types of in-depth sensitivity and importance anal-
ysis methods and on the implementation of the respective graphical tools embedded in the system, to
help the patient fully understand the recommended strategy. A preliminary assessment of PANDEX by
six genetic consultants demonstrated a relative unwillingness to work with PANDEX (mean = 2.16 ± 0.98
(SD), on a scale of 1–5), but a tendency to agree with its recommended strategies (mean = 3.48 ± 1.4) and
with its capability to provide insights into the recommended strategies (3.28 ± 1.23). PANDEX was con-
sidered by the consultants to be a potentially useful tool for patients.
 2008 Elsevier Inc. All rights reserved.1. Introduction
1.1. The decision analysis task and its implications for the prenatal
testing domain
Virtually synonymous with thinking, decision-making is central
to all human intellectual activity; as such, it is not the sole province
of any speciﬁc domain, but rather, is inherent to many ﬁelds,
including medicine. Decision-making research, in contrast to re-
search based on problem-solving, focuses on the nature of the deci-
sion’s outcome to a greater extent than on the process of ﬁnding
solutions. Patel et al. [1], in analyzing some of the differences
between the two research domains, have pointed out that deci-
sion-making research focuses on cognitive issues, such as why
and how decisions deviate from a standard of rationality. They also
differentiated between three important kinds of knowledge in the
decision-making domain: factual knowledge, which relates to
known facts; procedural knowledge, which deals with how to per-
form various activities; and conceptual knowledge, which refers to
the ability to integrate new information with prior knowledge.
The concept of shared decision-making in the domain of medical
consultation and treatment refers to the care provider-patient
partnership in the process of decision-making and in the assump-ll rights reserved.tion of responsibility for the decision that is made jointly [2]. It is
self-evident that for cases entailing several treatment options that
may have signiﬁcantly different effects on a patient’s life, the pa-
tient’s preferences must be taken into consideration. An additional
issue is the extent of the information shared with the patients.
Detailed explanations about their conditions and the possible out-
comes must be supplied to the patients. The explanations beneﬁt
the patients by helping them cope with the problem and by assist-
ing with self-care, to name but a few advantages.
A care provider-patient partnership in making decisions about a
treatment can take different forms [3]. Several models have been
put forward to describe patient behavior in the context of meeting
with a care provider to discuss a medical problem, often involving
decisionswithmajor implications regarding thepotential outcomes.
The three best-known models are the paternalist model, in which
there is no partnership (the patient puts his/her complete trust in
the care provider tomake the best treatment decision), the informed
model, inwhich thecareprovidermerely transmitsmedical informa-
tion to the patient without aiding in the decision-making process,
and the sharedmodel, inwhichboth thepatient and the careprovider
have legitimate investments in the treatment decision, and as such,
they both declare their preferences concerning the possible out-
comes. Thesemodels have been likened to the roles played by differ-
ent patients interacting with a patient–decision support system [4].
An additional model—that recommended by Emanuel and Emanuel
[5]—is the so-called deliberative model, in which the patient is
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models notwithstanding, it is our premise that regardless of the
quality of the patient-doctor interaction, informed consent and its
variations is somewhat meaningless without appropriate computa-
tional support. This observation is especially relevant when consid-
ering the various biases demonstrated in humandecision-making as
poignantly pointed out by Tversky and Kahneman [6] and by other
researchers.
The consideration of patient preferences is arguably one of the
most important parts of improving a patient’s quality of life [7].
In this context, it is necessary to distinguish between two different
issues: ﬁrst, the assessment of patient satisfaction with (or utility
for) speciﬁc states of health; and second, patient preferences for
speciﬁc treatments. Perhaps the most important concept in deci-
sion-making is the utility function, which provides a way of attach-
ing measures to possible health outcomes in a way that is
consistent with the decision maker’s preferences and that can be
implemented using decision models [8]. For the implementation
of utility theory in decision models it is necessary to elicit a utility
function that suitably represents the speciﬁc decision maker. Util-
ity functions can be represented either as continuous, i.e., logarith-
mic or exponential, functions (in cases where there is a continuous
domain of results, as in ﬁnancial problems) or as discrete functions
(perhaps the more common situation in medical models). Utility
functions may be elicited in a number of ways. Simple methods,
such as the visual analog scale method, require the decision maker
to simply rate the quality of life (in medical domains) for each pos-
sible outcome. There are also more sophisticated methods used in
the elicitation process. The classiﬁcation technique suggested by
Chajewska et al. [9], for example, forms clusters of similar utility
functions in a database and asks the patient several key questions,
thereby quickly relating a new patient to a certain cluster of pa-
tients (i.e., a utility function), thus reducing the number of neces-
sary questions by an order of magnitude, with only minimal, if at
all, reduction in the optimality of the proposed strategy.
Informed consent is important to the process of shared deci-
sion-making: although patients may not always want to take the
ﬁnal responsibility for the details of all clinical decisions, the care
provider has a moral responsibility to honor patient preferences
and to support informed participation in the decision-making pro-
cess [10]. As Doyal points out, the actual practical beneﬁt of a given
medical regime may have little to do with whether the patient
chooses it, but once the potential for such a choice is removed,
the patient is subjected to a moral harm that may even be accom-
panied by psychological suffering.
Encouraging patient involvement in the decision-making pro-
cess is vital and poses several challenges for care providers [11].
Extra time and effort may be necessary to elicit the patient’s pref-
erences, which, in some cases, may differ from those of their care
providers. Care providers who intend to involve their patients in
the decision-making process, therefore, require professional train-
ing to prepare them for the added responsibility and challenges.
Decision support systems may also help overcome the potential
problems inherent in shared decision-making. Kaplan et al. [12]
claim that the problem at hand is the increasing need to help pa-
tients navigate complex decisions, even though the health care sys-
tem embodies well-known limitations with respect to delivering
salient facts and providing guidance. They suggest two possible
solutions for decision support: developing tools based on informa-
tion resources—internet or decision aids—and coupling these tools
with decision counseling (either by care providers who have had
informed-choice training or by third party decision counselors). El-
wyn et al. [13] presented a study that has provided substantial
consensus about a framework of quality criteria for patient deci-
sion aids. The criteria are available as a users’ checklist and are
being used as a guide to developers of decision support.1.2. The prenatal testing domain
Although built on top of a generic architecture, the current
study focuses on the medical domain of prenatal testing, which
is a part of the genetic consultation domain. Encompassing the
diagnostic tests available to pregnant women to diagnose diseases
in the fetus, this knowledge-rich domain still involves numerous
uncertainties that are expressed as probabilities of diseases, test
sensitivities and speciﬁcities, and the risks involved in invasive
tests. Decisions made within the domain entail potentially far-
reaching consequences, including test-related risks to the fetus,
the chance of termination, and a variety of other medical and eth-
ical issues. In addition, it is important that the medical establish-
ment understand the mother/parents preferences regarding the
possible outcomes of the decisions.
Multiple decision-analytic studies have been conducted in the
prenatal testing domain, starting with Pauker’s suggestion to view
it as a classical utility trade-off problem [14]. Kuppermann et al.
[15] has put an emphasis on the discussion, by the clinicians, of
the various possible outcomes with the patients (such as the like-
lihood of future birth in the event of pregnancy loss), and on the
consideration of the preferences of the individual woman. Kupper-
mann et al. has also investigated racial-ethnic differences in prena-
tal diagnostic test use [16].
Our current model, as used in this study, focuses on a limited
portion of the prenatal testing domain, although still encompass-
ing more than just Down syndrome; we currently include mostly
variations of neural tube defects (NTDs) and Down syndrome.
The monetary costs of the tests are not taken into account in the
model, which focuses on the patient’s decision, but their complica-
tions and information-oriented implications are considered.
The tests included in the model (in chronological order of appli-
cation) are:
1. Triple screen test—performed between the 15th and 20th weeks
of pregnancy. Its result is expressed as a relative risk
2. Amniocentesis—performed between the 16th and 20th weeks
of pregnancy
3. Second trimester ultrasound scan—performed between 19th
and 24th weeks of pregnancy.
Each of the tests listed above has a particular sensitivity and
speciﬁcity for each disease. Amniocentesis carries a 0.5% risk of
spontaneous abortion, representing the main source of disutility
(risk) in the prenatal testing process.
The prenatal diagnostic domain provides ample opportunity for
the decision-making process, since there is usually sufﬁcient time
to consider the alternatives, and the patient’s preferences (in this
case, those of the parents) are of crucial importance.
1.2.1. Biases in the prenatal testing domain
Many decisions are based upon beliefs regarding the possibili-
ties of uncertain events. People tend to use heuristic principles to
simplify the complicated task of assessing probabilities and fore-
casting values, but such principles may lead the decision maker
to erroneous, possibly biased conclusions. Kahneman and Tversky
[6] presented three types of bias—representativeness, availability,
and anchoring and adjustment. Representativeness, which is the de-
gree to which an instance of a class is representative of or similar
to class members, may cause care providers to ignore the existing
probability of a disease. For example, in the domain of prenatal
testing, even when assuming the extreme (and perhaps unlikely)
scenario of a particular test speciﬁcity of 99.99% (i.e., only 1 in
10,000 is a false positive) and a very high sensitivity of 99.9%
(i.e., only 1 in 1000 is a false negative) for a woman with a proba-
bility of 0.005 (at the age of 38) for Down syndrome, the positive
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2% chance that the fetus does not have Down syndrome, given a
positive test result. This result would be even more marked at
younger ages, when the prior probability of disease is much lower;
e.g., at the age of 30, with a Down syndrome probability of 0.001,
since the positive predictive value would be only around 90%. An
availability bias occurs when the estimate of one event is inﬂu-
enced by similar events easily recalled from the past. This might
happen when the genetic consultant has recently encountered sev-
eral cases of Down syndrome. An anchoring and adjustment bias re-
fers to the insufﬁcient adjustment of an estimate to an initial
anchor value, such as happens when a care provider starts with a
very low probability for a particular diagnosis and then fails to ad-
just the post-test probability appropriately, even when given com-
bined evidence from several independent genetic and clinical tests.
Other kinds of bias were described by Chapman and Elstein [17]:
biases concerned with judging the likelihood of events, such as
hindsight bias, and biases that concern preferences and values,
such as the framing effect, in which different descriptions of the
same pathological case may result, correspondingly, in the care
provider giving different diagnoses.
All of these biases further emphasize the imperative need for an
objective computational infrastructure to support a shared deci-
sion-making process effectively, and to assist (both the care pro-
vider and the patient!) in understanding its semantics.
1.3. Explanation and exploration in decision support systems
Providing a computerized infrastructure to compute strategies,
however, is not enough. Computerized systems often do not sufﬁ-
ciently explain their problem-solving processes and results to the
human user. The conclusions reached by the system do not always
support the primary expectations of the user, and occasionally they
even provide surprising results. When such ‘‘misunderstandings”
occur between the user and the system, explanations can either
yield insights that allow the user to feel comfortable in disregard-
ing the computer’s advice, or they can provide assurance that the
computer’s reasoning is logical and robust regarding possible mod-
iﬁcations of a patient’s previously determined probabilities or pref-
erences. Thus, it is important that the results be explained to the
user in terms that can be understood.
It is possible to provide tailored explanations and advice based
on a decision analytic model without requiring the user to under-
stand the underlying technical and mathematical aspects of deci-
sion theory [18]. Research has indeed been performed in the
domain of explanations in decision models. The REX system [19],
for example, utilizes a method of explanation known as recon-
structive explanation. According to this approach, the system sup-
plies the user with a result that has been calculated according to a
certain model or theory. The explanation of the results is built from
scratch, but not necessarily according to the way the solution was
reached. The underlying concept of this approach is that explana-
tions to the user should render the results as understandable as
possible and increase the user’s conﬁdence in the system’s results.
The INSITE system [20] emphasizes the relation between the initial
evidence and the results in an explanatory manner. Langlotz et al.
[18] introduced a computer program that uses symbolic reasoning
techniques to generate qualitative explanations of the decision
analysis results.
One of the most important explanation methods is sensitivity
analysis. This type of analysis is, in fact, a test of the validity of
the model’s conclusions over a wide range of assumptions about
probabilities and utilities [21], which are actually the model’s vari-
ables. However, in contrast to sensitivity analysis in economic
models, in medical models the (patient’s) utility function itself,
namely, the pre-assigned values of the outcomes, can also be ex-plored, since patients are seldom conﬁdent of their own prefer-
ences towards outcomes that are unfamiliar to them. Another
way to deﬁne the purpose of sensitivity analysis-based conclusions
is to indicate the range of the model’s variables (single variable or
more) over which the conclusions apply. A different way of
performing such an analysis was introduced by Sonnenblick and
Henrion [22] in a model examining pollutant effects. Their model
(importance analysis) is probabilistic and uses distributions to
express uncertainties of the variables. Importance analysis is pre-
sented as a tool for examining the correlation between uncertainty
in inputs and the resulting uncertainty in outputs. The variables in
the model are then ranked according to their importance (their
sample correlation with the outputs).
Collaboration between researchers from Stanford University,
Washington University, and the Palo Alto Health Care System ini-
tially produced the PORTAL system and later, its successor, the
ALCHEMIST system. PORTAL, an interactive Web-based interface
that enables remote use of decision models, was implemented in
the framework of the Cardiac Arrhythmia and Risk of Death Patient
Outcomes Research Project [25]. Users of PORTAL can change the
base-case input variables and then view the correspondingly al-
tered health and economic results. Additionally, the users can per-
form and view sensitivity analyses on the numerous model
variables. Also an interactive Web-based system, ALCHEMIST [26]
combines information from the decision model and the decision
analyst to automatically create an annotated algorithm of the opti-
mal test or treatment strategy, as determined by the decision mod-
el. ALCHEMIST also creates a balance sheet of beneﬁts, harmful
actions, and costs; lists the variables to which the guideline is sen-
sitive; and graphically represents the change in the expected utility
as the value of each variable is changed along its sensitivity analy-
sis range.
1.4. Medical decision-making in the prenatal testing domain
Kuppermann and Norton [23] showed that prenatal testing
guidelines need to be re-evaluated. It has long been accepted that
women at the age of 35 years or older, at the time of delivery,
should be offered prenatal diagnosis through amniocentesis, but
Kuppermann and Norton [23] claimed the concept of the ‘‘35-
year-old threshold” was based on assumptions and circumstances
that are no longer valid. Newer screening tests, such as the triple
screen test, provide much better individual risk information about
chromosomal and other abnormalities in the fetus than the mater-
nal age alone. In addition, the parents’ preferences towards having a
life-long disability child, or towards termination of the pregnancy,
are typically much more important for the overall decision, such as
whether to have amniocentesis. Studies of women’s preferences
indicate that numeric risk is not always the primary consideration
in a woman’s decision about prenatal diagnosis.
Norman et al. [24] focused on the domain of prenatal testing in
the Stanford PANDA project, which provided an inﬂuence diagram
model that implemented an analytic framework and which recom-
mended strategies for selecting a suitable strategy for prenatal
testing. A number of diseases were considered in PANDA, and a se-
quence of decisions about tests and interventions was constructed.
The PANDA software offered the functionality of analyzing com-
plete decision strategies rather than analyzing only individual
decisions. The software produced an optimal strategy for an indi-
vidual decision maker, and supported some minimal amount of
sensitivity analysis to examine changes in initial variables (such
as the age of the mother) and their possible effects on the original
results.
Thus, the domain of decision-making in medicine in general,
and in prenatal testing in particular, is hindered by the lack of suit-
able decision support systems. There appears to be a need for a
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mended strategy to a particular user on the basis of an underlying
decision model, her initial personal medical data, and her elicited
utility values for the possible outcomes. Such an application should
also offer a variety of analysis methods to assist the user in under-
standing the recommended strategy and thus enhance their conﬁ-
dence in the recommendation. These methods must include the
ability to change initial values (probabilities and utilities) to test
their effect on the recommended tailored strategy (i.e., perform
sensitivity analysis) as well as additional advanced methods that
provide an inkling as to why, for example, was not offered a com-
mon strategy.1.5. The objectives of the current research
To support the above needs, we have developed PANDEX, a
Web-based decision support system in the domain of prenatal test-
ing. PANDEX enables shared decision-making and offers the user
(whether the care provider or the patient) a variety of analysis
methods and explanatory and exploratory tools. Emphasis is
placed on the real-time tailoring of the system to individual
users—their needs, and their understandings, or misunderstand-
ings of the therapeutic option and of the different outcomes. The
user has access to a variety of different analyses, including sensitiv-
ity (1-, 2- or 3-way), threshold, importance, statistical (using the
system’s repository), and probabilistic analyses.
The main focus of the current study is on presenting the PAN-
DEX methodology, its implementation, a theoretical evaluation of
its soundness, and a preliminary evaluation of its potential useful-
ness by demonstrating its use to genetic consultants on several
representative cases. A full evaluation of the value of the PANDEX
system to patients is planned.
Although the particular medical domain in which the PANDEX
system was tested was that of prenatal testing, the resulting appli-
cation is generic and hence applicable to a variety of medical
domains.
The research questions posed by such an undertaking, which
are aimed at answering in the current study, are therefore the
following:
1. Can an application based upon a Bayesian probabilistic model,
such as an inﬂuence diagram or a decision tree, provide a sufﬁ-
cient basis upon which to build a dynamic, patient-customized
strategy and to generate further analysis?
2. In addition to the strategy recommendation itself, can we add
other applicable modes of explanation to that strategy?
3. Is such a shared decision-making application in the domain of
prenatal diagnosis considered at least potentially useful by
health care professionals in that domain?
2. Methods
PANDEX manages a dialog with its user, who is given a general
introduction both to the relevant medical domain and to the pos-
sible choices (actions) and outcomes relevant to that domain. Next,
PANDEX elicits the user’s utilities regarding the possible outcomes.
Through the above dialogue, a strategy is recommended to the
user. PANDEX also provides its users with explanatory and explor-
atory tools. These tools assist the users in analyzing the results and
enable them to perform dynamic sensitivity analysis, in which the
effects of one or more parameters (probabilities or utilities) on the
recommended strategy and their expected utility are demon-
strated. PANDEX enables users to change some of their initial data,
entered at the beginning of the process, to test the effects of thechanges on the recommended strategy. Other, optional explana-
tory features offer a particular user a statistical comparison with
previous users of the application, give her an idea of the risk in-
volved in choosing a particular course of action over another, and
provide an importance analysis that highlights the proposed strat-
egy’s most inﬂuential variables.
2.1. PANDEX—the distributed architecture
The PANDEX architecture is a rather generic architecture for
shared decision support, which is constructed from several inde-
pendent components that communicate with each other based
on the software’s multi-tier architecture (Fig. 1). The bottom tier
consists of two components, the decision model, which is an inﬂu-
ence diagram converted into a decision tree model (in our case, by
the TreeAge DataTM software), and the database (in our case, a
Microsoft SQL server database). The decision model is used to per-
form the different calculations and analyses. The database layer
serves two very different functionalities: (1) the knowledge base
that stores the metadata about the model (e.g., disease prior prob-
abilities, test properties, etc.); (2) the runtime application’s data
repository, in which the user session data is stored. Communication
between the PANDEX user interface (UI) and the internal decision
model are performed, in our particular implementation, by the
TreeAge Data Interactive API, which is the API component for com-
munication with Data tree models. The middle tier is the computa-
tional engine that communicates with the lower tier to retrieve
and update data and that performs calculations and analyses with
the aim of transferring the relevant data to the UI, which consti-
tutes the upper tier. The engine is based on code written in C#
and ASP.NET.
PANDEX provides a generic foundation for creating models in
different medical domains. The application’s analysis engine is
completely independent of the particular domain’s speciﬁc knowl-
edge base or decision model. Therefore, PANDEX can be adapted to
anymedical domain via several straightforward changes in the sys-
tem setup and knowledge base.
2.2. The PANDEX decision-making model
Since the core decision model in the PANDEX system is a Bayes-
ian probabilistic model, important initial probabilistic knowledge
and patient preferences are required for calculating expected utili-
ties in the model. First, the initial default probabilities for each of
the diseases must be provided in the knowledge base. In the case
of the prenatal testing domain, the probability of Down syndrome
is known from a conversion table that relates current maternal
age to the probability of a fetus with Down syndrome. The initial
probability of an NTD disease in the fetus is modiﬁed according to
whether the pregnant woman is taking folic acid. If she is, then
the probability of a NTD decreases from the prior of 0.001–
0.00092. If the triple test has already been performed, then a smal-
ler decision model is used, without the triple test. In this case, the
probability (risk) of Down syndrome is provided directly from the
test result. The probability of NTD is calculated according to the
predictive results—positive or negative—of the two tests. To obtain
the current NTD probability, the Bayesian calculation is performed
using a small decision tree model. Two common probabilistic test-
diseasemeasures, sensitivity and speciﬁcity, are used by PANDEX to
gauge the predictive capability of the tests. PANDEX allows the care
provider to update the model’s probabilities at the beginning of
each session with the patient, and it also allows them to modify
the default knowledge base. There are several possible decision
points in this model for each of the three tests—triple screen,
amniocentesis, ultrasound; these decision points include whether
to perform the test and whether to terminate the pregnancy.
Fig. 2. A small part of the PANDEX inﬂuence diagrammodel. The triple test decision
node and its related resulting chance nodes, and deterministic nodes.
Fig. 1. General scheme of the PANDEX architecture.
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which is linked to a personal utility value (from 0 to 100) that is
assigned to it by the individual user during the preference elicita-
tion phase, as demonstrated later in this section (this value indi-
cates the speciﬁc user’s preference regarding this outcome). The
six possible outcomes in the current model are as follows: birth
of a healthy baby, birth of a baby with Down syndrome, birth of
a baby with a NTD, birth of a baby with multiple diseases, termina-
tion of a pregnancy with a healthy fetus, and termination of preg-
nancy with a fetus having Down syndrome and/or a NTD.
The model was initially constructed as an inﬂuence diagram,
which is a convenient method for working with domain experts
and for inserting modiﬁcations. Using the Data software tool, the
inﬂuence diagram was later transformed into a decision tree mod-
el. The ﬁrst test that can be performed in the prenatal testing do-
main (and therefore, the ﬁrst decision node in the inﬂuence
diagram) is the triple test (Fig. 2). The decision model is not sym-
metric, because if the triple test is not performed, the two subse-
quent chance nodes (triple test Down syndrome result and triple
test NTD result) become irrelevant, and should be skipped over un-
til the next decision node. Each result chance node is preceded by
its corresponding disease chance node. Such a modeling method,
based on the requirement for the prior disease probability in the
result node, enables calculation of the result probability using
the test’s sensitivity and speciﬁcity. Each of the deterministic
nodes (those with double borders, Fig. 2) represents a probability
value required to calculate the possible outcomes of the chance
node. Probabilities are taken into consideration within the deﬁni-
tion of each chance node, by using the test’s predictive probabili-
ties. The model assumes binary behavior for each of its chance
and decision nodes, and therefore, each node must have exactly
two results/alternatives. For example, the two possible results of
the triple test decision are to undergo the test or not to undergo
the test. Likewise, the spontaneous abortion chance node has two
possible outcomes: spontaneous abortion either has or has not
occurred.
The ﬁnal decision node refers to an elected termination of the
pregnancy. After all the test decisions will have been made, and
the results of any tests taken are known, termination is the ﬁnal
decision before the diagram’s utility node (Fig. 3). Each of the
deterministic nodes preceding the utility node holds a utility value,
ranging from 0 to 1 (multiplied for convenience by 100, in the
interface), for a speciﬁc possible outcome. If the user has already
undergone the triple test, the application will use a reduced ver-sion of this model, without the initial decision triple test decision
node and without the two subsequent result chance nodes. The
inﬂuence diagram model is converted automatically in Data soft-
ware to a decision tree model. This is the decision model that PAN-
DEX uses in all the analysis processes.
Fig. 4 displays a condensed version of the resulting decision tree
(the complete tree is beyond the display limits of this page). The
nodes are ordered chronologically, with each decision node
(square) followed by its two alternatives and each chance node
(circle) followed by its two results. Therefore, for each test per-
formed, test decision nodes are followed by two chance nodes rel-
evant to the test’s results—one for Down syndrome and one for
NTDs. Final nodes (diamonds) are the leaf nodes in the model. Each
of these nodes has a utility value according to the values of the
variables that represent the utility values (e.g., ‘‘health,” ‘‘ds,”
‘‘term”. . .). This generic (i.e., not patient-speciﬁc) model does
not show the expected values of strategies and outcomes. A small
feature added to the tree model is the cost of the triple test
and the ultrasound tests. Since these two tests—unlike the
Fig. 3. A section of the prenatal diagnosis inﬂuence diagram, containing the
pregnancy termination decision node, followed by the ﬁnal utility node (which is
diamond shaped).
Fig. 4. The decision tree model and an example of displaying a recommended
strategy. The overall decision tree is displayed using a standard hierarchical
representation. The keyword ‘‘preferable” denotes the root of a recommended
(maximal-utility) sub-tree. For example, here a triple test can be performed or not.
If performed as recommended (‘‘Triple test is preferable”), then either a positive or a
negative NTD test result is returned. If positive, the DS triple test result is
considered as well; if that is also positive, an amniocentesis procedure is
recommended, etc.
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have a price of some small e for ﬁnal nodes that are descendants
of one of these tests. The utility for such a ﬁnal node is its original
value 0.0001. Thus, use of the tests is discouraged unless it
provides a positive beneﬁt.
2.3. The PANDEX graphical user interface and its underlying analytical
methodologies
The PANDEX user interface (UI) can be divided into several
components: User-tailored strategy creation wizard—collects user’s initial
data (e.g., demographic data, tests that the user has undergone),
elicits the user’s utilities (related to the model’s outcomes), and
ﬁnally displays the calculated strategy tree to the user. When
the wizard is started, a session object is created for the current
user that holds all the data of the user that is accumulated dur-
ing the wizard’s steps.
 Strategy viewer—displays the recommended strategy as a tree.
 Analysis tool suite—based on the recommended strategy, offers
many possible analyses of the recommended strategy. It
includes also the ‘‘what if”.
 Strategy comparison tool which enables users to change some of
their initial values (i.e., probabilities, utilities, tests performed)
and examine the recalculated strategy, based on the updated
details.
A typical PANDEX scenario includes the following steps:
 Step 1 of the strategy creation wizard is used to introduce the
user to the domain’s diseases and tests. It also contains a link
to a page that enables the user to update the initial probability
values (test sensitivities and speciﬁcities) either solely for the
current user’s session or for all users. This Web page is intended
for care providers or others with expert domain knowledge and
not for patient use.
 Step 2 is the initial step that elicits objective data from the preg-
nant woman. The data are used to calculate the initial disease
probabilities. Results of tests already administered to the user
can also be entered here. The next three steps refer to the PAN-
DEX utility elicitation process.
 Step 3 of the wizard is the ﬁrst stage of the utility elicitation pro-
cess. All possible outcomes are displayed to the user in as a list
of buttons, and the user (pregnant woman) has to rank them one
by one, starting from the best and ending with the worst possi-
ble outcome. The perfect health outcome functions as the top
anchor. This step produces a ranked list according to user pref-
erences for each outcome. Before continuing to the next step,
the user can choose to ‘‘ﬁne tune” her initial ranking by moving
outcomes up or down the ranked scale with the triangular arrow
buttons, located beside each ranked outcome.
 Step 4, the second stage of utility elicitation, enables the user to
assign utility values to the ranked outcomes by using the visual
analog scale method to elicit user preferences. The user is pre-
sented with four visual analog scales, each for a speciﬁc out-
come. The worst ranked outcome (from step 3) is not ranked
in each of the visual analog scales and instead serves as the bot-
tom anchor (representing the 0% point). The top anchor for the
scales is the perfect health outcome (the 100% point). The user
has to drag each of the bars’ edges (with the mouse) to the loca-
tion on the scale best representing her preference (see Fig. 5).
Thus, the scale presented to the user in the second stage is a
‘‘blown up” version of the segment that refers only to the rele-
vant outcomes (whose minimal utility value is in fact much
higher that 0). This linear magniﬁcation assists in eliciting the
user’s speciﬁc preferences. Fig. 5 demonstrates this step in the
UI.
After eliciting all quantitative preferences towards all outcomes,
the ranking implied by these preferences is compared to the out-
come ranking speciﬁed as an ordered list in Step 3, for validation
purposes. If contradictions are discovered, the user is alerted and
has a chance to modify the values. In any case, the quantitative val-
ues are the ones used for the rest of the process.
 Step 5 displays the ranking implied by the quantitative pref-
erences elicited in Step 4 as a table that summarizes the implied
Fig. 5. Example of the four visual analog scales (one for each possible condition of the born fetus) that the user is presented with during the utility elicitation phase. The worst
ranked outcome, which serves as the bottom anchor in the visual analog scales (representing the 0% point) in this example, is ‘‘Birth of a baby with multiple diseases”. The
best outcome is birth of a baby with perfect health. The ﬁgure displays the ranked utilities, after the user has already dragged the analog scale bars, using the mouse, to the
point on the scale considered closest to her preferences. (As the bar is dragged, the number in the legend below the scale changes.) This particular user has given the outcome
‘‘Birth of a baby with Down’s syndrome” the value of 2 on a scale of 0–100, thus ranking it as the second worst one, just above the worst outcome, ‘‘birth of a baby with
multiple diseases” (as shown in the bottom bar). After eliciting all quantitative preferences towards all outcomes, the ranking implied by these preferences is compared to the
outcome ranking speciﬁed as an ordered list in the previous step, for validation purposes.
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‘‘ﬁne tune” the values, using ‘‘” and ‘‘+” buttons, and can then
re-sort the utilities to examine their resultant ranking. Submission
of this 5 step Web form triggers an optimal strategy computation
and yields the strategy recommendation tree.
After the user has completed the wizard’s ﬁve-step form, and
her utility values have been elicited, she is transferred to the Rec-
ommended Strategy view screen (Fig. 6). The strategy is displayed
in tree view form, where chance nodes are split into two paths, and
decision nodes continue only as single—optimal decision—paths
(the decision that maximizes the decision node’s expected value
(EV)). Recommended decision nodes are highlighted with a
‘‘thumbs up” symbol to their left.
Fig. 6 displays the recommended strategy within a simulated
scenario for a 38-year old woman, who is already the mother of
ﬁve children and who comes from a religious family, and for whom
an abortion has a relatively low value, even when given a high
probability of a diseased baby. However, mainly for the value of
knowledge and for preparatory purposes, she chose to use PAN-
DEX. Her ﬁrst decision is the triple test decision. Since this test’s
cost is negligible, and considering her initial data (the age of 38
has nearly a 0.6% chance of a fetus with Down’s syndrome), it is
recommended that she perform the triple test. Only in the scenar-
ios where she receives a positive DS triple test result, is it recom-
mended that she continue to the amniocentesis test, which has
several implications, as described before. It can be seen that if
the results from the amniocentesis test are a negative AFP result,
but a positive karyotype result (i.e.,—a positive indication for a
DS diagnosis), it is recommended that she perform the ultrasound
test as well, in order to gain more evidence. In the case of both the
AFP and the Karyotype being positive, it is recommended that she
perform an abortion, without continuing to the ultrasound test.
In the upper right corner of the screen, there are three useful
viewing options related to the strategy tree. The ﬁrst reduces the
current view to a critical decisions tree view, which displays only
branches that end, either by choice of the patient or as a result of
the amniocentesis test, in a pregnancy termination. The second
and the third viewing options simply expand or collapse all tree
nodes, correspondingly.
On the left side of the Recommended Strategy screen, the links
in the ‘‘Decision analyses” menu refer to the ﬁve different analysisscreens. To use these links effectively, the user must ﬁrst select a
decision node in the tree and then select the desired analysis
screen, which is based on the selected decision node. A review of
the PANDEX analysis screens follows.
2.3.1. Variables affecting expected utility
The ﬁrst analysis screen relies on a one-way sensitivity anal-
ysis at the selected decision node. This means that the expected
utility’s sensitivity to values of the variables at the selected
node will be displayed. The displayed results are separated into
two tables, one for utility variables and the other for probability
variables. Each table row displays the variable’s name, its cur-
rent value, and the change in the expected value at the current
decision node as a result of an incremental decrease in the va-
lue of the variable. A corresponding horizontal bar graph repre-
senting the required change in EV is also displayed. PANDEX
performs a one-way sensitivity analysis for each variable Xi at
decision node A as follows:
1. The current value of X: VAL(X)
2. Calculate the expected value at node A: EV (A)
3. Change the value of X to VAL(X) * 0.99
4. Calculate the new expected value at node A: NEV (A)
5. Calculate the incremental difference: DIFF = (EV (A)  NEV (A))/
VAL(X) * 0.01.
2.3.2. Multi dimensional sensitivity analysis
Several of the analysis screens (for example, the screen for
variables affecting expected utilities) allow the user to select
two or three variable rows for analysis, after which the user
clicks the ‘‘Multi-variable sensitivity analysis” button to continue
to the multi-dimensional sensitivity analysis screen. A list of the
selected variables is displayed, each row showing the variable’s
current value and containing two textboxes for entering the low-
er and upper bounds of the range for which this variable will be
analyzed. When three variables are chosen for analysis, the ﬁrst
two variables will be denoted as ‘‘X” and ‘‘Y” axes and a sensitiv-
ity analysis table would be displayed for them, while the third
row will be marked as the ‘‘Z” axis row. A set of discrete ‘‘Z” val-
ues would be created, and each resulting sensitivity analysis ta-
ble would be based on a certain value of this ‘‘Z” variable (The
Fig. 6. An example of the ‘‘recommended-strategy” tree view. Chance nodes (an example is marked with ‘‘1”) are split into two paths, while decision nodes (an example is
marked with ‘‘2”) continue only as single (optimal decision) paths (the decision that maximizes the decision node’s expected value (EV)). Recommended decision nodes are
highlighted with a ‘‘thumbs up” (an example is marked with ‘‘3”) symbol to their left. In this case, the recommendation to this particular patient, based on her preferences and
personal risk factors, is to perform the amniocentesis procedure only if the result of the triple test is positive for DS. If the amniocentesis karyotype diagnosis is positive, and
no spontaneous abortion due the procedure has occurred, the recommendation to this particular patient is to perform the ultrasound test as well.
Fig. 7. Multi-dimensional sensitivity analysis table. Here, for a particular value of the probability of spontaneous abortion due to the amniocentesis (AC) procedure, the user
can explore the various combinations of the ranges of the variables ‘‘ [utility of] termination of a pregnancy with a healthy fetus” and ‘‘ [utility of] termination of a pregnancy
with a diseased fetus”. Each cell includes a colorful and symbolic representation of whether the decision in question (here, whether to perform AC) is Yes, No, or Maybe
(dependent on the precise values of the parameters in question). In this case, clicking on the large right hand arrow would navigate the user into a similar table, but for the
next value of the probability of spontaneous abortion due to AC. Clicking on a particular cell would zoom into a similar table, but with reﬁned (sub) ranges for the
‘‘Termination of a pregnancy with a healthy fetus” and ‘‘Termination of a pregnancy with a diseased fetus” parameters (in this case, these represent the patient’s preferences).
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we usually use six as default). The user may change the order
of the variables.
After setting the desired range for each of the analyzed values,
the user clicks the ‘‘Analyze” button to view the analysis results,
which are shown as an analysis results table (Fig. 7). Colored cells
within the table refer to certain ranges of the X- and Y-axis vari-
ables. Each table screen displays the results according to the
user-deﬁned ranges of the ‘‘X” and ‘‘Y” variables and (when rele-
vant) a single Z-axis variable value. Users can navigate between
the various ‘‘Z” values by clicking the large arrows on either side
of the table (see Fig. 7). Clicking a particular cell in any table zooms
into the corresponding ranges of the X- and Y-axis variables, recur-
sively. At any zoom level, the cells are color coded as follows (see
Fig. 7):
 Green (p): perform the current action at this decision node, e.g.,
if the decision is whether to undergo a test (e.g., undergo amnio-
centesis), green signiﬁes that the answer is ‘‘Yes”, namely, taking
this action, (i.e., performing the test). Red (X): do not perform the action in the decision node (i.e., the
answer is ‘‘No” for the decision node).
 Blue (): the expected values of both options are equal. That is,
the answer can equally be ‘‘Yes” or ‘‘No” (‘‘Indifferent”).
 Gray (?): ambiguous decision, meaning that in this range of the
X and Y variables, changes for different values, and thus a further
zoom-in is needed to detect the precise transition point(s).
Note that this explanatory sensitivity analysis model assumes
that each decision node is an action whose semantics are ‘‘per-
form” or ‘‘do not perform”. The PANDEX knowledge base is thus
designed accordingly.
The PANDEX-based three-way sensitivity analysis (for variables
X, Y, and Z at decision node A) is performed as follows:
1. Each of the variables is assigned lower and upper bounds for the
current analysis process
2. The speciﬁed interval is split into ﬁve equal segments, assigning
each variable a set of six values. The output is thus three sets of
values (six values per variable, or axis)
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tested, and the optimal alternative for decision node A is
selected. If two end points of a consecutive range imply differ-
ent choices, the range is colored as gray; else it is colored as
green (both end points are ‘‘Yes”), or blue (both end points
are ‘‘Indifferent”).
2.3.3. Variable threshold values
This analysis screen scans for threshold values of the model’s
variables at the selected decision node. It displays the variables
for which only relatively small changes in value are required to
modify the recommended alternative. For each variable’s row, a
corresponding horizontal bar graph is displayed (Fig. 8) that illus-
trates the difference between the current value of the variable and
the threshold value. Using a one-way sensitivity analysis, the
underlying analysis tests where (and if) a change in the variable
causes a change in the recommended alternative for the current
decision node. The steps for a PANDEX threshold analysis (for each
variable Xi at decision node A) are outlined below:
a. The upper and lower bounds of the variable and the number
of intervals to split this section are plugged into the decision
model
b. Lower bound: if X is a utility variable then MAX (VAL(X)
0.1,0.01); if X is a probability variable then VAL(X)/10
c. Upper bound: if X is a utility variable then MIN (VAL(X)
+0.1,0.99); if X is a probability variable then VAL(X) * 10
d. Number of intervals = 10
e. The decision model output is a set of thresholds for the dif-
ferent values of X. The algorithm takes the threshold closest
to the current value of X and returns this value and the EV at
node A for this value of X.
2.3.4. Variables most affecting the recommended strategy
This analysis screen displays the ﬁve most important variables,
(those that contributed most to the EV of the recommended deci-
sion) at the current decision node, based upon the importance
analysis algorithm. This screen also presents comparative statisti-
cal information for the variables displayed. Like the former analysis
screens, this one is also divided into upper and lower sections for
utility and probability variables, respectively. For each variable
there are two corresponding horizontal bar graphs (Fig. 9): one
represents the statistical range for the current variable for former
PANDEX users, who had been recommended strategies similar to
that of the current user, and the other graph represents the range
for former users for whom strategies different from that of the cur-
rent user had been recommended.Fig. 8. This ﬁgure demonstrates threshold variables for a speciﬁc scenario, at the amnio
variables. As the upper bar demonstrates, for this speciﬁc user, if the probability for spon
recommended that she not perform this test. On the other hand, as we see in the lower b
probability is 0.01), it would have also been recommended that she not go through thisThe idea of the importance analysis is to use a heuristic algo-
rithm that calculates the variables exerting the strongest effects
on the current strategy. In particular, for a set of tree nodes
{N1. . .NJ} and a set of variables {X1. . .XN}, the algorithm calculates
the effect of each variable Xi on the current decision at any speciﬁc
decision node Nk. This measure is called the importance of variable
Xi at node Nk (IMPORT (i, k)). Given a particular strategy, the algo-
rithm, using a recursive visit order, performs a top-down scan of
all the reachable nodes in the tree and accumulates the importance
rates for each of the variables in the model.
The importance rate is calculated by comparing optimal alter-
natives at each decision node to the second-best alternative at that
node (assuming binary decisions). In fact, the algorithm calculates
the discrete marginal utility (DEV/DX) at each decision node for
each variable Xi assuming that the rest of the parameters are left
unchanged (as in one-way sensitivity analysis). The calculated
importance at each decision node is multiplied by the path proba-
bility of this node for the accumulation action. This probability as-
sumes the decision node’s path is used in the optimal strategy (i.e.,
only optimal alternatives are taken). For each variable Xi in the
model, whether a probability or a utility variable, the algorithm
takes the form (At the current decision node Nk):
1. Calculate the node’s path probability (starting from the root):
PROB (Nk) (i.e., PPi —the accumulated product of the nodes’
probabilities along the path leading to this node: at each deci-
sion node multiple by 1; at each chance multiple by the node’s
probability relative to its predecessor node)
2. For the variable Xi, calculate D(Diff):
a. Calculate: D(EV) = | EV1  EV2 |. EV1 is the expected value
of the ﬁrst alternative, and EV2 of the second alternative
of the decision node Nk, is chosen
b. Change the value of Xi: Val0(Xi) = Val (Xi) * 0.9999
c. Calculate: D0ðEVÞ ¼j EV1  EV02 j, where EV01 and EV02 are the
new expected values of the ﬁrst and second alternatives,
respectively
d. D(Diff) = (D (EV)  D0(EV))/(Val (Xi) * 0.001)
3. Calculate WEIGHT(i,k): PROB (Nk) * D(Diff) for the variable Xi at
node Nk
4. Calculate IMPORT(i,k): sum up the weight result to the accumu-
lated sum of weight values (calculated recursively for all the
descendent decision nodes of node Nk):
IMPORTði; kÞ ¼WEIGHTði; kÞ þWEIGHTði; kþ 1Þ þ . . .
þWEIGHTði; JÞ; for nodes Nk . . .NJ:centesis decision node. In this case, there are interesting results for two probability
taneous abortion increases above 0.0095 (her current probability is 0.005), it will be
ar, if the probability for Down’s syndrome had been lower than 0.0073 (her current
procedure.
Fig. 9. Here we observe a certain user’s results for the amniocentesis test decision. When focusing on the utility section, it can be seen that there are two effecting variables:
birth of a baby with Down’s syndrome, and termination of a pregnancy with a diseased fetus. Each of these variables has two related horizontal bar graphs, one dark in color
(marked as ‘‘1”) and the other lighter (marked as ‘‘2”). The dark blue one represents the statistical range for the current variable’s value, for former PANDEX users, who were
recommended a strategy like the current user. The other bar represents the range for former users who were recommended different strategies from the current user. The
vertical line (marked as ‘‘3”) marks the location of the current value, relative to the ranges’ values. The columns ‘‘Lower statistical bound” and ‘‘Upper statistical bound” show
the numeric values for the relevant bar’s bounds. The value ranges for users with the same strategy as the current user’s demonstrate a very low range for birth of a baby with
Down’s syndrome, and a very high one for termination of pregnancy with a diseased fetus.
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X-i, it returns a set of weights for each variable. PANDEX takes
the top ﬁve variables and presents them in the interface.
An option that is available to users while calculating the impor-
tance is the ‘‘Change demographic ﬁlter” link. Clicking this link
opens a new window with a set of combo boxes, one for each
demographic factor (e.g., age, education). The user can select a
demographic ﬁlter (e.g., set the ethnicity), and all the correspond-
ing statistical results on the analysis page will be calculated
according to that ﬁlter. This might be useful when trying to under-
stand the relative importance of certain parameters within a par-
ticular demographic context.
2.3.5. Population-based comparative analysis
Similar to the affecting variables screen, this analysis screen
also displays statistical comparisons and important variables at
the decision point. It summarizes the results of the former analysis
screen, which is overloaded with details for the new user (pregnant
woman) who usually wants only an overview of her statistical
comparisons and the relevant affecting variables. The key idea here
is to explain a (possibly surprising) strategy in terms of how the
patient’s parameters are similar to or differ from those of other
demographically similar patients. Two pairs of vertical bar graphs
appear in the upper section of the screen. The ﬁrst bar graph pair
shows the number of other users with demographic data (i.e.,
age, education, etc.) similar to that of the current user’s who were
counseled to adopt the same recommended strategy. The second
pair of graphs displays the same data for all users of the application
(without any demographic ordering). On the left side of this screen,
the user’s initial demographic data, including her age, are dis-
played. Values in each of the combo boxes can be changed and
recalculated, and the ﬁltered results refer to the newly selected
values. Filter parameters may also be changed by removing the
ticks from the checkboxes to the right of each demographic data
row, and subsequent results will not be ﬁltered for those parame-
ters that are not ticked. On the lower section of this screen, the
utility variables that most strongly affect the decision are dis-
played. For each variable, the mean values for the current ﬁltered
population and for the whole population are shown. The statistical
analysis employed in this analysis screen exploits the PANDEX
repository for previous users of the application and performs sim-
ple statistical measures, for example, displaying the mean value for
a variable and the variable’s statistical lower and upper bounds
(AVG  STDV, AVG + STDV, correspondingly).
2.3.6. Comparing alternatives
The ﬁnal analysis screen shows the user the possible outcomes
that can result from the selected decision. The probability of each
outcome is displayed when either the recommended decision
(‘‘Yes”) or its negative (i.e., ‘‘No”) is selected.
Fig. 10 demonstrates the results screen of the analysis. Each re-
sult row displays two horizontal bars: the dark, upper bar repre-sents the outcome probability when the recommended option is
chosen, and the light, lower bar is the outcome probability when
the opposite option is selected. The underlying risk analysis algo-
rithm has a single decision node and calculates the probabilities
for each of the model’s alternative outcomes i.e., when the optimal
decision is or is not selected at the current node. Either way, the
algorithm assumes that the options selected at decision nodes
are those with higher EVs. The algorithm takes the form:
1. Starting with the root node of the tree, begin by scanning the
entire tree, top to bottom.
2. Accumulate the path probability as you go down the tree.
3. Each instance of a leaf node with the outcome OUT prompts the
addition of the accumulated probability PROB to the value rel-
evant to OUT, PROB(OUT).
4. The algorithm returns a set—{PROB (OUT1), PROB (OUT2)-
PROB (OUTn)} for all the possible n outcomes for the optimal
alternative and a similar set for the second-best alternative.
Note that the analysis is performed in the context of evidence
already known at this node. Here, for example, the probability
for NTD and DS has already been increased, and an ultrasound
might prevent the otherwise recommended strategy of terminat-
ing the pregnancy.
The value screen in PANDEX enables the user (pregnant wo-
man) to change certain initial data (elicited throughout the strat-
egy creation wizard’s steps) and test the effect, i.e., whether the
changes alter the recommended strategy. The user may even
choose to update the new values, and, accordingly, PANDEX creates
a new strategy tree in addition to the existing one. When a new
strategy is calculated and displayed for the current user, PANDEX
records the old strategy, and the user may navigate between the
two.
3. Preliminary evaluation of the PANDEX system
The evaluation of PANDEX was two-fold: a semi-theoretical
assessment of its validity, and a preliminary semi-clinical assess-
ment by health care providers in its current medical domain.
3.1. The Semi-theoretical assessment
The ﬁrst entailed a semi-empirical validation of the application
as a reliable decision support tool that provides its user with valid
results. The PANDEX results were validated by comparison with
those obtained from the original decision tree model for two differ-
ent scenarios that were run in both applications. For both the
one-way sensitivity and threshold analyses, an excellent match
was obtained between the results of PANDEX and those produced
by the underlying analytical system. Additionally, comparison
analysis demonstrated the inherent consistency of the PANDEX
system for different analysis modules. Finally, in the decision
Fig. 10. Example of the alternatives’ comparison results, comparing the probability of obtaining various outcomes when applying the recommended strategy to the
probability of obtaining them using another strategy. In this case, the context is a node in which evidence has already accumulated regarding a very high probability for NTD
and DS. Thus, performance of an ultrasound test might decrease this probability, and possibly (P = 0.241. . .) lead to the birth of a healthy baby. Not performing the ultrasound,
however, would force this particular patient to terminate the pregnancy given her particular preferences and the available information at that point.
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strated monotonic behavior. The importance rate is based upon the
expected value difference (D(EV)) for each variable in the recom-
mended strategy when compared to the second-best value of that
variable. The results proved to be monotonic for variables with
either positive or negative importance rates.
3.2. The preliminary semi-clinical assessment
A preliminary practical assessment constituted the second eval-
uation phase, which evaluated PANDEX functionality as a decision
support tool designed to provide the user with recommendations
and detailed analyses. However, since an assessment of the value
of the system in a clinical setting was out of the scope of the cur-
rent study, and requires signiﬁcant additional extensions, as ex-
plained in the Section 4.6, we assessed its potential value for
health care professionals in its current clinical domain.
The semi-clinical evaluation phase included a simulation exper-
imentwith several health care providers. The experiment took place
at ‘‘Hadassah”Medical Center, Jerusalem, at the genetic consultation
clinic. Six genetic consultantsparticipated in this experiment. Before
beginning the work with PANDEX, each of the consultants received
an overview of the PANDEX project and an explanation about the
application and its purposes. Each of the genetic consultants was
presented with three or four simulated, but realistic, scenarios of
women who had come for genetic consultation.
Table 1 displays the different scenarios considered in this eval-
uation. The six outcomes, whose utilities for each patient are listed,
are those described in Section 2.2.Table 1
Simulated demographic data and utility functions for the four different practical evaluatio
Scenari
Age of pregnant woman 27
Pregnant woman uses folic acid during pregnancy Yes
Utility value for birth of a healthy baby 100
Utility value for termination of a pregnancy with a healthy fetus 80
Utility value for termination of pregnancy with a diseased fetus 30
Utility value for birth of a baby with a NTD 5
Utility value for birth of a baby with Down syndrome 2
Utility value for birth of a baby with multiple diseases 1The data for each scenario were loaded into the PANDEX system
through the user’s initial data elicitation screen. The utility values
were then set using the preference elicitation screens. This led to a
presentation of the recommended strategy to the genetic consul-
tant for each scenario. After examining the strategy tree, several
additional analysis features, such as expected utility’s affecting
variables or variables’ threshold values were displayed to the ge-
netic consultant.
After ﬁnishing the review of the recommended strategy and
analysis for each scenario, the genetic consultant ﬁlled a short
questionnaire containing two questions: The ﬁrst one referred to
the consultant’s agreement with the recommended strategy sug-
gested by PANDEX for the current scenario. The second question
examined the consultant’s opinion concerning the PANDEX
analysis tools. Ranks for each question were given on a scale of
1–5 signifying lowest to highest agreement, respectively.
After ﬁnishing reviewing all of the scenarios, the consultant was
asked for her general opinion about the project, and then she ﬁlled
a ﬁnal questionnaire. The purpose of this questionnaire was to get
feedback from the genetic consultant about her attitude toward
decision support systems such as PANDEX, and the possibility of
combining such applications in medical care. The ranking format
of these questions was the same as in the initial (short, scenario-
speciﬁc) questionnaire.
Each encounter with a consultant lasted between 45 and
60 min.
Analysis of the scenario questionnaires showed that, on aver-
age, the consultants tended to agree with the strategies recom-
mended by PANDEX (mean = 3.48 ± 1.4 (SD)) and with the factn scenarios.
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tional insight into the recommended strategy (3.28 ± 1.23). Analy-
sis of the ﬁnal questionnaires ﬁlled out at the end of the session
showed that although the consultants were not particularly com-
fortable about incorporating a decision support system such as
PANDEX into their counseling work (2.16 ± 0.98), they tended to
agree that an application with a broader domain knowledge base
could be applicable in the domain of prenatal testing
(3.16 ± 1.72) and that PANDEX could serve as a useful tool for
use by the patient prior to meeting with the genetic consultant
(3.33 ± 1.21). Indeed, some of the consultants explicitly stated this
opinion.
In addition to the quantitative evaluation results, additional in-
sights were obtained from the free-text comments and further dis-
cussion with the genetic consultants.
Interestingly, the comments indicated that the genetic consul-
tants, who are just as prone to probabilistic calculation errors as
any other care providers, were nevertheless still unwilling to put
their trust in the computer results. Some of the consultants even
claimed that there was an error in the calculations PANDEX per-
formed when, for example, they saw that after a positive karyo-
type result in the amniocentesis test (i.e., an indication for a
diagnosis of Down’s syndrome), there was still a non-negligible,
positive chance for delivery of a healthy baby. This assertion is,
of course, incorrect and somewhat surprising, given the consul-
tants’ experience. We consider the implications of such comments
in Section 4.
Several of the consultants explicitly suggested that the analyses
performed by the PANDEX system would be of more interest to the
patients than to them. We elaborate on these comments as well in
Section 4.
This is perhaps a welcome conclusion, since the main purpose
of the analysis tools was indeed to provide the patient with further
insight into the thinking behind the consultant’s recommendations
(although when used in a care provider-patient meeting, PANDEX
results could also provide information to the care provider). The
conclusion is that the extra insight granted by the analysis tools
of PANDEX might be of interest mainly to patients, although it
may also beneﬁt care providers.4. Conclusions and discussion
Recall the research questions originally posed in this study. We
can now consider the results of the current study in the light of
these questions. We can then further discuss their implications.
4.1. Answers to the research questions
1. Can an application based upon a Bayesian probabilistic model,
such as an inﬂuence diagram or a decision tree, provide a sufﬁ-
cient basis upon which to build a dynamic, patient-customized
strategy and to generate further analysis?
To examine this question, we introduced PANDEX, a Web-
based, real-time implementation of our framework in the prenatal
testing domain. The semi-theoretical assessment of PANDEX
proved that it produces valid results that correspond to its under-
lying Bayesian model. In particular, we have demonstrated its
capability to generate a recommended strategy tailored in
real-time to current user data, on which further sophisticated sen-
sitivity analysis methods can be based.
2. In addition to the strategy recommendation itself, can we
add other applicable modes of explanation to that strategy?As described in detail in Section 2, the PANDEX system includes
several advanced modes for sensitivity analysis and explanation.
PANDEX supplies additional insights, based on sensitivity analysis,
heuristic importance analysis, and statistical analysis, that collec-
tively provide a tool for explanation and exploration of the model
and its recommended course of action. One of the interesting
explanation modes involves comparison of the recommended
strategy to the strategies recommended to other users, speciﬁcally,
comparison of differing user attributes that might provide insight
to different recommended strategies. Other explanation modes in-
volve various types of importance and sensitivity analyses. All of
these explanation modes were all fully implemented and evaluated
within both the semi-theoretical and the semi-clinical assessments
and were found to be feasible and valid.
3. Is such a shared decision-making application in the domain
of prenatal diagnosis considered at least potentially useful
by health care professionals in that domain?
Although the PANDEX system in its current implementation did
not score very highly with respect to immediate value to genetic
consultants, the consultants demonstrated a tendency to agree
with its recommended strategies (mean = 3.48 ± 1.4 on a scale of
1–5) and with its capability to provide insights into the recom-
mended strategies (3.28 ± 1.23). PANDEX was considered by the
consultants to be a potentially useful tool for patients. We are thus
encouraged in the feasibility of enhancing the system and evaluat-
ing it in the future in a clinical setting.
4.2. Broader implications of the current study
In almost every medical domain today, patients and care pro-
viders confront difﬁcult choices involving objective mathematical
and probabilistic considerations and subjective issues related to
patient attitudes to different medical procedures and their possible
outcomes. Care providers often lack both the necessary informa-
tion and the processing abilities [27,28] to make a properly in-
formed decision. Cognitive biases also affect the rational and
computational limits of human decision makers [6,17]. Likewise,
unsatisfactory care provider-patient communication thwarts pro-
ductive decision-making. Ultimately, care providers may ignore
patient preferences for procedures or outcomes. These problems
are exacerbated by the lack of accessible decision support models
that can assist patients and care providers during or even after
the visit to the care provider. Even when a computerized decision
support tool is available, people do not understand the problem-
solving processes used, or the results presented, by the computer,
a fact that reduces user conﬁdence in the application’s recommen-
dations. The gaps in, and drawbacks of, medical decision-making
today provided the motivation for the PANDEX project. The under-
taking, which resulted in a Web-based application that is built
upon a decision support model, was driven by the following
requirements:
 A normative, decision support model that takes all the required
relevant data into consideration, and performs correct
calculations
 A utility-based decision support model that accepts as input
user preferences regarding possible outcomes
 A shared decision-making process, in which care provider and
patient work together to achieve informed consent about impor-
tant medical decisions
 A Web-based application with a user-friendly interface to dis-
play the proposed patient-customized strategy of the decision
support system
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ized strategy.
As noted in Section 4.1, we believe that many of these require-
ments were indeed met by the PANDEX framework and its current
implementation, although, of course, an assessment by patients in a
clinical setting is still necessary. However, our tentative conclusion
from the preliminary semi-clinical evaluation is that as an initial
step in a consultation, either at home or at the clinic with the assis-
tance of an application expert, PANDEX has the potential to en-
hance the consultation process itself.
The preliminary evaluation results also showed that the genetic
consultants agreed with the need to understand and elicit the pref-
erences of the pregnant woman concerning the possible outcomes
in the pregnancy and birth process. This result implies that the no-
tions of shared decision-making and its importance, including the
need to obtain informed consent, are understood by the genetic
consultants.
The discrepancy noted in the semi-clinical evaluation between
probability theory and the practical intuition of the genetic consul-
tants (such as not believing in the possibility of false positive re-
sults of genetic tests) might be due to the fact that false positive
results in prenatal diagnosis that lead to termination of the preg-
nancy are perhaps less likely to be discovered or at least explicitly
noted by the original referring consultant. However, such miscon-
ceptions regarding the positive (and probably also the negative)
predictive value of diagnostic tests suggest that if genetic consul-
tants, in particular, and care providers, in general, better under-
stood the biases and the resultant mistakes when they reach
decisions without a supporting tool, their trust in decision support
models might increase.
As noted in Section 3, several of the consultants explicitly sug-
gested that the analyses performed by the PANDEX system would
be of more interest to the patients than to them. This suggestion
perhaps provides a welcome encouragement with respect to the
study’s main objective, since the main purpose of the analytical
tools was indeed to provide the patient with further insight into
the thinking behind the consultant’s recommendations (although
when used in a care provider-patient meeting, PANDEX results
could also provide information to the care provider).
Considering a broader perspective of the medical domain, the
PANDEX framework might lead to potential beneﬁts in most med-
ical domains that involve input from patients regarding their pref-
erences. It is applicable in domains in which the patient is
confronted with deliberative decisions regarding, for example,
whether to perform a risky medical procedure, such as amniocen-
tesis in the prenatal testing domain, or use a particular hyperten-
sive therapy medication. PANDEX is not applicable, however, in
domains requiring quick decisions or in which patients’ prefer-
ences regarding various outcomes or treatment modalities are
irrelevant. Therefore, this tool must serve as a part of a complete
decision-making process that includes consultation with the care
provider.
As care provider-patient meetings have evolved into the brief
encounters they are today, the web-based PANDEX system can off-
set the reduction in personal contact since it is equally accessible
from the patient’s home and during a follow-up intensive meeting
with a decision consultation specialist (as previously suggested by
other researchers, such as Woolf et al. [12]), perhaps even before
meeting the care provider.
In addition, the explanation and exploration modes inherent in
PANDEX, especially the comparison function based on similar case
data in the patient case repository, can signiﬁcantly contribute to
the patient comprehension that is necessary for a fully shared deci-
sion process. For example, a patient may wonder why she is not
being offered amniocentesis as part of the recommended strategy.Comparative explanation can be used to show her that her utility
function is signiﬁcantly different from those of similar patients
who were offered other recommendations. Finally, PANDEX-based
analyses can provide solid grounds for obtaining the patient’s truly
informed consent, which, as previously noted, has strong moral
underpinnings.
4.3. Comparison to related work
We have mentioned in Section 1.3 of the introduction several
former applications that have been developed in the domain of
explanation in decision support systems. Here we wish to compare
the PANDEX application to the earlier mentioned ones.
We have referred to several systems that have been developed
in order to provide comprehensible explanations for the results
provided by the underlying decision model to their end users.
The REX [19] system’s main advantage is its ability to create expla-
nations that are independent of the underlying model. Similarly for
the INSITE [20] system and for the system introduced by Langlotz
et al. [18]. Therefore, the main advantage of such systems is in clar-
ifying the results to the user. Nevertheless, all three systems lack
analysis tools beyond computation of optimal strategies, and do
not explicitly consider the utility function of the user, or the possi-
bility of modifying it. In addition, these systems did not use, of
course, a web-based user-friendly interface to bring the results to
the end user, as in PANDEX.
The PANDA project offered software that produces an optimal
strategy, based upon an underlying Bayesian decision model. As
in PANDEX, PANDA focused on the domain of prenatal testing,
however, the sensitivity analysis was not interactive, the explana-
tion capability was quite limited, and the system was conﬁned to a
particular site.
The PORTAL project offered a web-based interactive application,
where the user can perform sensitivity analysis on model variables.
PORTAL’s extension, the ALCHEMIST application, presented within
a web-based interface several analysis screens, which resemble the
PANDEX UI, such as the change in the expected utility as a result of
a change in the model’s variable value, and a recalculation of strat-
egies after changing a variable’s value. ALCHEMIST provided a
method for automatically analyzing a decision model based, for
example, on actual, published data, and for displaying the results
of the analysis in an intuitive, compact format as a recommended
guideline. However, it lacked the ability to elicit user preferences,
as PANDEX does, and thus to customize the resulting guideline to
a particular patient; its analysis capabilities were limited, and
the UI was quite simple.
4.4. Limitations of the current study
Despite the potential advantages of the PANDEX system, there
are still several issues that remain unresolved, and overcoming
them will require additional study or a different solution.
The utility elicitation module is insufﬁcient in its current form
and requires signiﬁcant improvements before the PANDEX system
can be freely used by patients. We are actively exploring several
avenues in this area, exploiting the state of the art techniques
and building on them to further enhance the validity of the utility
elicitation process.
The analysis interface is not immediately comprehensible to
either patients or care providers, and contains large amounts of nu-
meric data. As pointed out by the genetic consultants, to be truly
useful, the model should include additional diseases and proce-
dures. Although PANDEX provides a ﬂexible architecture for
introducing new medical models, it is currently still a burdensome
task to do so (we intend to develop knowledge management
modules that are easier to use). The user interface of the current
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more comprehensible and user-friendly.
Needless to say, the current evaluation focused only on various
functionality aspects and on an assessment only by one potential
user group, namely genetic consultants, and not by the main target
user group, namely patients. In addition, the group of consultants
for the evaluation was a rather small one—only six consultants par-
ticipated in it. Once the core-content and interface issues are re-
solved, we will be able to obtain patient feedback and assess
other potential beneﬁts, such as enhancing the patient’s conﬁdence
in the robustness of their decision. We elaborate more on our
intentions regarding a future clinical evaluation in the Section 4.6.
The ﬁnal disadvantage which should be mentioned is a rather
subtle one, and is common to all similar decision models: PANDEX
implicitly forces the user to deﬁne a complete chronological order
of the tests and decisions. This implicit order is currently rather
rigidly set in the underlying model. Although in the prenatal deci-
sion-making domain most temporal relationship are due to purely
clinical constraints, such as the ability to perform amniocentesis
within a particular time window, it would be useful in general to
enable partial or even completely ambiguous order relations
among decisions, for example (e.g., could the ultrasound decision
be taken later, if clinically feasible?). This might be important for
generation of a general guideline.
4.5. Advantages of the current study
Although PANDEX focuses on the domain of prenatal testing, its
generic infrastructure makes PANDEX applicable to almost any
medical domain and decision model, as long as that model can
be represented as a decision tree (or equivalently, as an inﬂuence
diagram). As an Internet-based application, PANDEX is equally
accessible both at home and in the clinic. After its results are tai-
lored to the current user, PANDEX displays the recommended
strategy in a comprehensible tree view manner.
PANDEX also features a powerful decision analysis explanatory
functionality based on sensitivity analysis, threshold analysis, sta-
tistical analysis, and comparative (with other patient cases) analy-
sis, thus providing the user with numerous tools to explain and
explore the recommendations. Such a capability, identiﬁed early
in our research as a prerequisite, is crucial in the medical domain,
in general, and for support of shared decision-making in particular.
4.6. Future work
Our future objectives include a full evaluation of the PANDEX
system in a speciﬁc medical domain, either the domain of prenatal
testing introduced here (which requires a signiﬁcant extension of
the knowledge base, to make the system fully usable) or any other
domain that involves crucial decisions related to risky medical pro-
cedures and to their possible outcomes and includes an opportu-
nity for deliberation by the patient. Measures for the beneﬁt of
such an evaluation might include, for example, the change in the
level of conﬁdence of the patients in the robustness of their deci-
sions, their level of comprehension of the reasons for the strategy
offered to them, the strength of the match between the strategy
they eventually chose and their preferences, the usability of the
interface by the patients and/or their care providers, etc. Such an
evaluation requires signiﬁcant resources and was of course out of
the scope of the current study, but will provide multiple insights
into the beneﬁts to patients of shared decision-analytical systems.
The user interface of the current implementation of the PANDEX
system has to be improved, and not only with respect to the strat-
egy recommended, but also with respect to elicitation of the pa-
tient’s preferences. We intend to do that enhancement as part of
the future clinical evaluation.A necessary prerequisite to the implementation of PANDEX in
medical clinics is care provider instruction and guidance, not only
regarding the application itself, but also about the importance of
correctly processing and calculating the probabilistic data, and
the possible errors in calculation people tend to make while per-
forming such calculations without the assistance of a technological
tool. This guidance may help increase both care provider accep-
tance of applications such as PANDEX and awareness of the miscal-
culations likely to occur when working without the aid of a
decision model.
A new study by our group is currently focusing on the prefer-
ence elicitation process with the aim of producing a better prefer-
ence elicitation module. Thus, patients could use the utility
elicitation module easily even in their own homes, and then con-
tinue their session with PANDEX at the clinic (using the analysis
screens) with the assistance of either the physician or an applica-
tion expert, that might help reducing concern arising from the
amount of numeric data, that may occur when patients operate
PANDEX by themselves
Furthermore, to exploit thepotentiallywide applicability of PAN-
DEX to any medical domain model requires the development of a
back-ofﬁce application that will assist domain experts in the task
of adding andmaintaining newmedical models to PANDEX. Several
additional features can be added to PANDEX, thereby increasing its
value. For example, allowing users to only partially constrain the or-
der of the tests and decisions is a potentially important feature. In
addition, including monetary considerations in the utility model
would add an important dimension to the strategy recommendation
process, since such considerations are indeed taken into account in
everyday medical decision-making, especially for procedures that
are not funded either by the government or by a healthmaintenance
organization. Finally, the creation of a persistent user proﬁle and its
long-term maintenance during future consultations could enable
several strategies to be proposed over time.
To conclude, we have introduced in this study a framework,
which is capable of offering customized strategies for patients in
suitable domains, and which includes a set of tools for explanation
and exploration of the recommended strategy. The framework was
implemented as the PANDEX system in the domain of prenatal ge-
netic consultation. Preliminary assessment by genetic consultants
suggested potential beneﬁts to patients in that domain, and vali-
dated the feasibility of a future evaluation of the system’s value
to patients in a clinical setting.
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